EU Research in Health

Transcription

1 EU Research in Health SANIT - Management in the Health Sector 2004 Prof. Magdalene Rosenmöller IESE Business School - Barcelona 2 SANIT EU Research 1

2 Overview EC Research Programmes Fourth Framework Programme Biomedicine and Health (BIOMED 2) Biotechnology Programme (BIOTECH 2) Esprit, the EU information technologies programme Telematics Application Programme (for Health Care) INCO - Cooperation with 3rd countries & international organisations Fifth Framework Programme Life - Quality of Life & Management of Living Resources IST - User Friendly Information Society INCO 2 - International Co-operation JRC - Joint Research Centre Sixth Framework Programme Quality of Life & Management of Living Resources Life Sciences, genomics and biotechnology for Health Information society technologies Nanotechnologies and Nanosciences, knowledge based multifunctional materials, new production processes and devices 7th Framework Programme Quality of Life & Management of Living Resources Technology Platforms Future of research - Building FP7 3 Fourth Framework Progamme Biomedecine and Health Programme (BIOMED) implemented under the Fourth Framework Programme ( ) ECU million BIOTECH 2 aimed to improve our basic biological knowledge of living systems and to increase productivity in a sustainable fashion, with respect to applications in agriculture, industry, health, nutrition and the environment. It also considered the ethical and socio-economic implications of biotechnology. Cell Factory 4 SANIT EU Research 2

3 Biotechnology Programme (BIOTECH 2) Cell factories Biological components of cell factories: Microbial & Animal Biochemical engineering components of cell factories Integrated cell factories Genome analysis Sequencing Function search In silico comparative analysis Plant and animal biotechnology Plant molecular and cellular biology Animal physiopathology ; Genome mapping, etc Cell communication in neurosciences, Development, Regeneration, Degeneration, Management of information Cell to cell communication in the nervous system Immunology and transdisease vaccinology Structural biology Prenormative research, biodiversity and social acceptance in vitro alternatives to animal experiments, biosafety, Microbial ecology, Biofertilizers, Biopesticides, Vaccines, Plants, Fish biotechnology for the environment, Biodiversity, Plants, Animals, Microorganisms, Social acceptance Infrastructures Information infrastructures, Information resources A European network of bioinformatics nodes Horizontal information resources: literature, directories, databases Genetic archives and stock centres Horizontal activities ELSA: ethical, legal and social aspects Public perception Socio-economic impacts 5 6 SANIT EU Research 3

4 Fifth Framework Programme Quality of Life & Management of Living Resources Food, Nutrition and Health Cell Factory Linking the Ability to discover to the Ability to Exploit Environment and Health Air pollution; Asthma & allergies; Electromagnetic fields; Cancer; Noise; etc Sustainable Agriculture, Fisheries and Forestry The Ageing Population and their Disabilities Area 7 Chronic and Degenerative Diseases, Cancer, Diabetes, Cardiovascular Disease and Rare Diseases Area 8 Research into Genomes and Diseases of Genetic Origin Area 9 Neurosciences Area 10 Public Health and Health Services Research Area 11 Research Relating to Persons with Disabilities Area 12 Biomedical Ethics and Bioethics 7 6th EU Research Framework Programme Life Sciences, Genomics and Biotechnology for Health 8 SANIT EU Research 4

5 What is FP 6 ( ) about? 1. Integrating European Research 13.3 billion Thematic priorities Health, food, environment, nano-technology, ICT, aeronautics, society 11.3 billion Other activites policy support and anticipating S&T needs, horizontal SME support, JRC, int. co-operation, etc. 2 billion 2. Structuring ERA 2.6 billion 3. Strengthening the foundations of ERA 0.3 billion 9 FP6 Priority 1 Life sciences, genomics and biotechnology for health 1.1 Advanced genomics and its application for health million 1.1.a Fundamental knowledge and basic tools for functional genomics in all organisms (550 million ) 1.1.b Applications of knowledge and technologies in the field of genomics and biotechnology for health (550 million ) 1.2 Combating major diseases million 1.2.a Application oriented genomic approaches to medical knowledge and technologies (755 million ) 1.2.b Combating cancer* 1.2.c Confronting the major communicable diseases linked to poverty (400 million **) * around 400 million earmarked for Cancer within Combating University major of Navarra diseases and Advanced Genomics ** including 200 million for EDCTP 10 SANIT EU Research 5

6 Lines of FP6 Advanced genomics and its application for health fundamental knowledge and basic tools for functional genomics in all organisms application of knowledge and technologies in the field of genomics and biotechnology for health Combating major diseases application-oriented genomic approaches to major diseases combating cancer confronting the major communicable diseases linked to poverty Budget: (indicative) Thematic Priority Life Sciences, genomics and biotechnology for health: EUR million Advanced genomics and its applications for health:1209 Combating major diseases: FP6 Priority 1 Life sciences, genomics and biotechnology for health Four calls for proposals ( ) 2255 million First call: closed 119 contract currently under negotiations, approximately 600 million with around 8 % going to SMEs 2700 participants including around 10 % SMEs 80 % of the proposals includes SMEs Second call: open with deadline 13 November 2003 approximately 400 million, more details presented later today Third and fourth call: 2004 and SANIT EU Research 6

7 SSP Scientific Support to Policies Research for policy support Main objectives: The activities under this heading will underpin the formulation and implementation of Community policies; in particular the common agricultural policy (CAP), the common fisheries policies (CFP), environment, energy, transport, health, development aid, consumer protection etc. Research in this area will be mainly carried out by means of Specific Targeted Projects and Coordination Actions. In duly justified cases, limited use can be made of Integrated Projects (IPs) and Networks of Excellence (NoEs) 13 Different Project under FP6 SSP Health Policy Ageing Macro AHEAD Micro HEALTH Basket Patient Mobility Quality in Europe SARS Research into policy the interface Organ Donation Communicable Diseases / Networks Other clinical / Epidemiology, etc.. 14 SANIT EU Research 7

8 15 e4p Project SSP Scientific Support to Policies European Commission FP6 SP1 The Future for Patients in Europe Europe for Patients, e4p Duration: 3 years, Feb Jan 2007 Benefits and challenges of enhanced patient mobility in Europe how the benefits can be increased how challenges can be addressed 16 SANIT EU Research 8

9 Project Objective to contribute scientific evidence that will enable policy makers at EU, national & regional level to take concerted and coordinated action to allow Europe s citizens / patients to benefit from enhanced mobility in Europe 17 Other Programmes related to Health INCO International cooperation in Dev Countries Marie Curie - Human resources and mobility European Fellowships International Fellowships Research Training Networks Conferences and Training Courses Excellence Actions DG Sanco - Public Health Programme Information systems Rapid Reaction to Health Threats Health Determinants INFSO - ehealth Education Leonardo da Vinci - Community Vocational Training Action Programme ( ) 18 SANIT EU Research 9

10 INCO Health Research in International Cooperation Health Systems & Health System Research Determinants of Health Implications of specific Health issues Impacts of interventions Health sector reforms Quality of Care and of services Inputs in health systems (HHRR, drigs., etc.) Research methods Citizen perspective and user involvement Health policy Issues North South, involvement, Sustainability, capacity building GRPP Getting research into Policy and Practice Health system research systems 19 INFSO Information Society ehealth europa.eu.int/information_society/eeurope/2005/all_about/ehealth/index_en.htm Health Cards Integrated care records Evidence based decisions Health portals Quality of Health Websites Telemedicine Nanotechnology 20 SANIT EU Research 10

11 The Future of Research in an enlarged European Union 21 The European Research Area In March 2000, the Lisbon European Council set the goal of becoming by 2010 the most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion. The project of creating a European Research Area, as proposed by the Commission in its Communication "Towards a European Research Area" was endorsed as a central element of The Lisbon strategy to achieve this goal. 22 SANIT EU Research 11

12 The European Research Area Objective European Research Area initiative: Creation of an "internal market" in research - area of free movement of knowledge, researchers and technology, with the aim of increasing cooperation, stimulating competition and achieving a better allocation of resources; Restructuring of the European research fabric, in particular by improved coordination of national research activities and policies, which account for most of the research carried out and financed in Europe; Development of a European research policy which not only addresses the funding of research activities, but also takes account of all relevant aspects of other EU and national policies. 23 European Research Area 3 Weaknesses: insufficient funding lack of an environment to stimulate research and exploit results fragmented nature of activities and the dispersal of resources Objective - 3 related and complementary concepts: the creation of an "internal market" - area of free movement of knowledge, researchers and technology, with the aim of increasing cooperation, stimulating competition and achieving a better allocation of resources; a restructuring of the European research fabric, in particular by improved coordination of national research activities and policies, which account for most of the research carried out and financed in Europe; the development of a European research policy which not only addresses the funding of research activities, but also takes account of all relevant aspects of other EU and national policies. 24 SANIT EU Research 12

13 Strategy Lisbon Strategy Strategic Vision for Life Sciences and biotechnology up to 2010 The most competitive and dynamic knowledge-based economy in the world capable of sustainable growth with more and better jobs, within a decade. 30 points Leadership in a sensitive area Advantages High Technologies Create growth, new jobs, Benefit a wide range of sectors Broader goals sustainable development 25 Scoreboard Human resources in RTD Researchers (FTE) per 1000 workforce New S&T PhDs per 1000 population aged years Public and private investment in RTD Total R&D expenditure in % of GDP Industry financed R&D as % of industrial output Share of government budget allocated to R&D (GBAORD) Share of SMEs in publicly funded R&D executed by the business sector (%) Venture capital-investment per 1000 GDP Scientific and technological productivity Scientific publications per million population Highly cited publications per million population European patents per million population US patents per million population Impact of RTD on economic competitiveness and employment Labour productivity (GDP per hour worked) in PPS Labour productivity (GDP per hour worked) annual average growth % Value added in high-tech industries as % of GDP Employment in high-tech industries as % of total employment Value added of knowledge intensive services as % of GDP Employment in knowledge intensive services as % of total employment Technology balance of payments receipts as % of GDP Technology balance of payments (exports-imports) as % of GDP Exports of high-tech products as % of world total 26 SANIT EU Research 13

14 Strategy 6 th FP Budget 17,5 billion Euros 5% of total public research spending in Europe Critical expertise, structural impact on research landscape in Europe + Participation SME, international scientific cooperation, research infrastructures, mobility & training of researchers Addresses issues such as Insufficient mobility, brain-drain, fragmentation & duplication of efforts, no transformation of research results into products and services More research for Europe Towards 3% of GDP EU, 1,9%, US 2.,7%, Japan 3% EU funds to be matched by national funds Cross border: nationals, and public / private World wide ban on human reproductive cloning 27 Strategic Vision 7 th Framework Programme Strategic Vision of the future 7th Framework Programme europa.eu.int/comm/research/future/themes/index_en.ht ml Biotechnology - europa.eu.int/comm/biotechnology/introduction_en.ht ml Technological Platforms Plants for the Future Innovative Medicines 28 SANIT EU Research 14

15 Why more industry in EC funded research? Important political targets for the EU We should become the most competitive knowledge based economy by biotechnology identified as major growth area together with information technologies The overall spending on R&D and innovation should reach 3 % of GDP by 2010 (2/3 of the contribution should come from the private sector) Research intensive life science/biotech SMEs play an important role in reaching the above goals and thereby contributing to growth, innovation and employment 29 What could be the benefits of industry participation in EC funded projects? Valuable results are lost today that should be translated to application and should be exploited whenever possible Early access to newly generated knowledge can increase the competitive edge for European industry/smes Good opportunities for training and expansion of recruitment base and for dissemination of new results, methods and technologies Better mutual understanding of the academic and industrial cultures can bring mutual benefits (e.g. timing of market entry for gene therapy) Involve European industry/smes more in research activities to stimulate the total investment in research and innovation 30 SANIT EU Research 15

16 What is the role of the EC in promoting and funding research? Funding agency Mainly supporting research done by multinational, multidisciplinary consortia in pre-defined areas through multi-annual framework programmes Framework Programme 6 (FP6), , has the objective to: strengthen the scientific and technological basis to increase the competitiveness of industry and encourage its international competitiveness while promoting research activities in support of other EU policies Policy maker European Research Area, 3% of GDP spent on R&D, Life sciences and biotechnology strategy, etc. 31 What do the EC have on offer as a funding agency? million dedicated to Life sciences, genomics and biotechnology for health research (Priority 1) Additional opportunities for life science/biotech SMEs in other Priorities such as nanotechnolgies, food, etc. Industrial participation in research can be funded between % depending on nature of work and type of project Special focus on SMEs with 15 % of the total budget earmarked for their participation > 85 million per year for SMEs in Priority 1 32 SANIT EU Research 16

17 Stakeholders of EU Research European Institutions European Parliament, European Economic and Social Committee, Committee of the Regions Member States Governments - eg. France Regions, eg. NRW - CAT - Universities and Research institutions Private sector Pharma & BioTech Companies Commission s Joint Research Centre (JRC) 33 Hindering Factors Long term success of biotechnology in the Union? EU Biotech Industry = late starter in early stage (company size, revenues, product pipelines) Biotechnology Global, highly capital intensive and knowledge based industry Problems: fragmentation, access to finance and intellectual property protection Member States Transpose legislation Biotechnology patents, authorisation of GMOs, etc. Intellectual property protection More funds needed Interface public research systems industry Insufficiently developed EU firms turn to US for collaboration not to other EU companies EU lags behind US in terms of patents and collaborative R&D projects, US = dominant lead in innovative activities Lack of international governance EU-US BioTechnology Consultative Forum 34 SANIT EU Research 17

18 Technology Platforms Technological Platforms a unique feature of the European Commission's biotechnology R&D programme Objective - to improve links between fundamental research and commercial applications in Europe and to help translate and accelerate new ideas into new products. participation from industry in the Biotechnology programme has increased significantly and the number of platforms has risen to Example TP The European NANOMEDICINE Technology Platform Nanobiotechnologies for Medical Applications * The European Plant Genomics and Biotechnology Technology Platform ** 36 SANIT EU Research 18

19 Industrial Platforms HAE Healthy Ageing Europe Industrial Platform ACTIP - Animal Cell Technology Industrial Platform LABIP - Lactic Acid Bacteria Industrial Platform YIP - Yeast Industry Platform PIP - Plant Industry Platform IVTIP - In Vitro Testing Industrial Platform BACIP - Bacillus Subtilis Genome Industrial Platform FAIP - Farm Animal Industrial Platform IPM - Industry Platform for Microbiology SBIP - Structural Biology Industrial Platform BBP - Biotechnology for Biodiversity Platform FIP - Fungal Industry Platform E.NIP - European Neuroscience Industrial Platform EBIP - Environmental Biotechnology Industrial Platform TSE IP - TSE Industrial Platform 37 Thank you for your attention! magda@iese.edu SANIT EU Research 19